The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: A systematic review

被引:13
|
作者
Joanne, Milverton [1 ]
Skye, Newton [1 ]
Tracy, Merlin [1 ]
机构
[1] Univ Adelaide, Adelaide Hlth Technol Assessment, Level 9,AHMS Bldg,North Terrace, Adelaide, SA 5005, Australia
关键词
Pompe disease; Enzyme replacement therapy; Juvenile; Systematic review; ACID ALPHA-GLUCOSIDASE; ALGLUCOSIDASE ALPHA; PATIENT; EXPERIENCE; PHENOTYPE; TRIALS; ADULT; TOOL;
D O I
10.1002/jimd.12027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimThe objective of this research was to determine the effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease (patients aged 2 to 18years at symptom onset) by systematic review. MethodsA systematic search was conducted according to a protocol designed a priori of bibliographic databases and search engines. Studies selected according to pre-specified criteria were assessed for quality and risk of bias using standardised appraisal tools. Data were reported according to PRISMA conventions (Liberati et al. in PLoS Med 6:e1000100, 2009) and synthesised using GRADE (Guyatt et al. in J Clin Epidemiol 64:380-382, 2011). ResultsOf 2537 titles screened, 1 case series and 16 case reports met the inclusion criteria. No studies reported on the impact of enzyme replacement therapy on the survival of juvenile-onset patients. Low level evidence found that respiratory function may improve or be maintained in the early months of therapy. Improved muscle function in the first 6 to 12months was also suggested, but results may be confounded by natural development. Patients with less severe baseline status and treated at a younger age showed more response than patients with more severe baseline status, treated as adults. ConclusionsInterpretation of the findings was hindered by the lack of good quality evidence. The available data suggests that some JOPD patients may benefit in the short term from ERT through improved muscle strength and a reduced need for assisted ventilation. A focus by clinicians on improved and more consistent evidence collection, and use of study designs tailored to rare conditions, would provide more definitive results.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [21] In utero enzyme replacement therapy in a fetus with infantile-onset Pompe disease
    Cohen, Jennifer L.
    Chakraborty, Pranesh
    Fung-Kee-Fung, Karen
    Schwa, Marisa E.
    Bali, Deeksha
    Young, Sarah
    Gelb, Michael H.
    Khaledi, Hamid
    McIntosh, Nathan
    DiBattista, Alicia
    Kelly, Deidre
    Smallshaw, Stacey
    Lianoglou, Billie
    Harmatz, Paul
    Kishnani, Priya S.
    MacKenzie, Tippi C.
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S33 - S33
  • [22] Effects of enzyme replacement therapy on bone density in late onset Pompe disease
    Avanti, Mahima
    Kimonis, Virginia
    Chen, Alice
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S24 - S25
  • [23] The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
    Wenninger, Stephan
    Gutschmidt, Kristina
    Wirner, Corinna
    Einvag, Krisztina
    Montagnese, Federica
    Schoser, Benedikt
    JOURNAL OF NEUROLOGY, 2021, 268 (08) : 2943 - 2950
  • [24] Enzyme Replacement Therapy in Five Adults with Late-Onset Pompe Disease
    Oboudiyat, Carly B.
    Pastores, Gregory
    Ferraris, Marrisa
    Sathe, Swati
    NEUROLOGY, 2010, 74 (09) : A519 - A519
  • [25] Enzyme replacement therapy for infantile-onset Pompe disease: Curse or cure?
    Willems, Jef
    Petros, Andy
    Brierley, Joe
    NEUROLOGY, 2008, 71 (05) : 380 - 381
  • [26] Weekly enzyme replacement therapy: a French patient with infantile onset Pompe disease
    Guffon, Nathalie
    Fouilhoux, Alain
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S53 - S53
  • [27] The UK experience of enzyme replacement therapy in patients with infantile onset Pompe disease
    Broomfield, Alexander
    Davison, James
    Fletcher, Joan
    Finnegan, Niamh
    Wood, Michelle
    Hensman, Pauline
    Clare, Beesley
    Church, Heather
    Tylee, Karen
    Burke, Derek
    Fenton, Matthew
    Champion, Michael
    Santra, Siakat
    Vijay, Suresh
    Abulhoul, Lara
    Chakrapani, Anupam
    Grunewald, Stephanie
    Cleary, Maureen
    Jones, Simon A.
    Vellodi, Ashok
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S24 - S25
  • [28] Effects of enzyme replacement therapy on bone density in late onset Pompe disease
    Kimonis, Virginia
    Avanti, Mahima
    Chen, Yanjun
    Knight, Margaret
    Mozaffar, Tahseen
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S84 - S84
  • [29] Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
    Dornelles, A. D.
    Junges, A. P. P.
    Krug, B.
    Goncalves, C.
    de Oliveira Junior, H. A.
    Schwartz, I. V. D.
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [30] Enzyme replacement therapy for the treatment of Pompe disease
    Angelini, Corrado
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (05): : 311 - 318